|
Base Line Characteristics of the Patients* |
||
| CHARACTERISTIC |
PLACEBO (N = 110) |
CINEOLE (N = 110) |
|
|
||
| Age – yr |
||
| Mean |
62.5 ± 10.2 |
62.2 ± 9.1 |
| Range |
40 – 79 |
41 – 79 |
| Sex – M/F |
75/35 |
66/44 |
| Weight – kg |
||
| Mean |
79 ± 16 |
79 ± 14 |
| Range |
48 – 120 |
52 – 113 |
| Height – m |
||
| Mean |
1.71 ± 8.8 |
1.70 ± 8.0 |
| Range |
1.48 – 1.90 |
1.54 – 1.92 |
| Years since appearance of COPD |
||
| Mean |
12.8 ± 9.7 |
13.6 ± 10.9 |
| Range |
1 – 56 |
1 – 59 |
| Severity of COPD [number of patients] |
||
| Moderate COPD (II) |
69 |
68 |
| Severe COPD (III) |
41 |
42 |
| FEV1/VC [%] |
58.0 |
58.7 |
| FEV1 [l] |
1.61 ± 0.5 |
1.62 ± 0.5 |
| FEV1 % predicted value |
54.4 |
54.9 |
| Reversibility (increase of FEV1 after inhalation of β-agonist) [%] |
5.5 |
4.5 |
| Allergies (number) |
10 |
9 |
| Pack years |
31.5 ± 19 |
31.3 ± 16 |
|
* Plus – minus values are means ± SD. | ||
Worth et al. Respiratory Research 2009 10:69 doi:10.1186/1465-9921-10-69 |
||